Susquehanna Fundamental Investments’s Standard BioTools LAB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,141	Closed	-$20K	–	1354
2022 Q3	$20K	Buy	+18,141	New	+$27.4K	﹤0.01%	1402
2022 Q1	$140K	Sell	39,039 -58,785	-60%	-$203K	﹤0.01%	1420
2021 Q4	$383K	Sell	97,824 -20,082	-17%	-$94K	0.01%	1028
2021 Q3	$777K	Buy	117,906 +910	+0.8%	+$5.99K	0.01%	990
2021 Q2	$721K	Buy	116,996 +97,400	+497%	+$521K	0.01%	1009
2021 Q1	$89K	Buy	+19,596	New	+$108K	﹤0.01%	1475
2020 Q4	–	Sell	-16,300	Closed	-$121K	–	1557
2020 Q3	$121K	Buy	+16,300	New	+$113K	﹤0.01%	1262

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JCP

Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Susquehanna Fundamental Investments's LAB Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Standard BioTools (LAB) in Q4 2022, closing a stake of 18,141 shares — an estimated $20K sold.

Susquehanna Fundamental Investments first reported a position in LAB in Q3 2020 and held it in 7 quarters. The position peaked at $777K in Q3 2021. 68 funds tracked by Wall St. Rank hold LAB as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Standard BioTools position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 18,141 Standard BioTools shares in Q4 2022, an estimated $20K.
Susquehanna Fundamental Investments first reported a position in Standard BioTools in Q3 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Standard BioTools position peaked at $777K in Q3 2021.
68 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.